A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance.

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after injury. For some, however, muscle development goes awry, leading to weakness, ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

When the gene editing tool CRISPR-Cas9 rocketed to fame more than a decade ago, it transformed biotechnology. Faster, cheaper, and safer than previous methods, the tool helped scientists gain insight ...

Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism. Transthyretin amyloidosis (ATTR) is a progressive disorder involving amyloid ...

Using CRISPR, Hebrew University of Jerusalem team finds PEDS1 enzyme linked to reduced brain size; study maps 331 genes ...

CRISPR Therapeutics (CRSP) earns a Hold rating as pipeline breadth grows but CASGEVY's launch remains slow and economically unattractive. CRSP’s in vivo editing platform shows strong early validation, ...

Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. CRISPR ...